| Professional Services Industry | Industrials Sector | Mr. Tang Yih Song CEO | SGX Exchange | - ISIN |
| Singapore Country | 15 Employees | - Last Dividend | - Last Split | - IPO Date |
Biolidics Limited stands as a distinguished entity within the realm of precision medicine medical technology, specifically dedicated to the development of an innovative portfolio of diagnostic solutions. With its operation spanning several vital segments, including Cancer, Infectious Diseases, and Laboratory Services, the company has established a robust presence. Biolidics Limited caters to a diverse clientele including academic and research institutes, hospitals, and laboratories. Its geographical footprint extends across Singapore, China, Hong Kong, Japan, the United States, and European Union countries. Since its establishment in 2009, Biolidics Limited has been headquartered in Singapore, where it continues to innovate and expand the frontiers of medical technology.
As part of its response to the global pandemic, Biolidics Limited offers Covid-19 PCR testing kits. These kits are designed to detect SARS-CoV-2 with high sensitivity and specificity, ensuring accurate diagnosis for effective disease management and control.
This automated device by Biolidics is calibrated to segregate and enrich cancer cells from the blood. The system supports the non-invasive assessment of cancer, providing a valuable tool for research, diagnosis, and monitoring of cancer progression and response to therapy.
Biolidics has developed antigen and antibody test kits to assist in the rapid diagnosis of various infectious diseases. These kits are crucial for public health, offering quick results that aid in the early detection and treatment of infections.
The company extends its diagnostics expertise through comprehensive laboratory services. This segment involves the provision of testing and analysis services, catering to the needs of its wide-ranging client base in the medical and research sectors.